Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tepotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA OKs FoundationOneCDx as Companion Dx for Tepotinib in NSCLC
    FDA OKs FoundationOneCDx as Companion Dx for Tepotinib in NSCLC

    21 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260521205015/en/U.S.-Food-and-Drug-Administration-Approves-FoundationOneCDx-as-a-Companion-Diagnostic-for-TEPMETKO-tepotinib-to-Identify-Patients-with-MET-Exon-14-Skipping-Alterations-in-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    21 May 2026
    Share Share
    FDA Approves FoundationOne®Liquid CDx for TEPMETKO® in NSCLC Cancer
    FDA Approves FoundationOne®Liquid CDx for TEPMETKO® in NSCLC Cancer

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118083116/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
    Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe

    05 May 2022

    // EMA

    https://www.ema.europa.eu/en/documents/overview/tepmetko-epar-medicine-overview_en.pdf

    EMA
    05 May 2022
    Share Share
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
    EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations

    18 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220217005798/en

    BUSINESSWIRE
    18 Feb 2022
    Share Share
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC
    TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC

    17 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211216005685/en

    BUSINESSWIRE
    17 Dec 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.